The 20 Best Clear Cell Sarcoma Doctors near Bronx, NY

Benjamin A. Gartrell, MD, is Director, Genitourinary Malignancy Program at Montefiore and an Assistant Professor of Oncology and Urology at our Albert Einstein College of Medicine. Since joining the Montefiore team in 2012, his expertise has been in treating genitourinary malignancies including prostate cancer, bladder cancer, renal cell cancer, and testicular cancer. He is also very active in translating science findings in collaboration with research colleagues at Einstein. In 2000, Dr. Gartrell received his Bachelor of Arts in Chemistry at the College of Wooster in Ohio. Following this, he attended the Northwestern University?s Feinberg School of Medicine, in Chicago, Illinois, where he received his Doctor of Medicine in 2005. His postgraduate training began in 2005 with an internship and residency in Internal Medicine at Case Western Reserve University, which he completed in 2008. He then completed a fellowship in Hematology/Oncology at Mount Sinai School of Medicine in 2012 and became Chief Fellow from 2010-2011. With a vast range of research interests, Dr. Gartrell focuses on translational research evaluating the significance of a novel immune checkpoint molecule in bladder cancer, evaluating the role of the autonomic nervous system in?prostate cancer, toxicities associated with anticancer therapies, and the impact of bone metastasis on patients with prostate cancer. His work has been published in a number of peer-reviewed journals, including the Journal of Clinical Oncology, Urologic Oncology, and European Urology. Dr. Gartrell also participates in community outreach to promote Prostate Cancer Awareness. Dr. Gartrell is rated as a Distinguished provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), WT1-Related Wilms Tumor Syndromes, Clear Cell Sarcoma, and Nephrectomy.

Guido Dalbagni is a Urologist in New York, New York. Dr. Dalbagni is rated as a Distinguished provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Upper Tract Urothelial Carcinoma (UTUC), Cystectomy, and Nephrectomy. Dr. Dalbagni is currently accepting new patients.

William Huang is a Urologist in New York, New York. Dr. Huang is rated as a Distinguished provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Renal Cell Carcinoma (RCC), Bladder Cancer, Prostate Cancer, Nephrectomy, and Cystectomy.

James McKiernan, MD, is the John K. Lattimer Professor of Urology and CEO of ColumbiaDoctors. He is also Senior Vice Dean for Clinical Affairs for Columbia University Vagelos College of Physicians and Surgeons. Dr. McKiernan graduated from Johns Hopkins University with a BA in biology and received his MD from Columbia University College of Physicians and Surgeons. He completed his training in urology and general surgery at NewYork-Presbyterian Hospital, followed by a urologic surgical oncology fellowship at Memorial Sloan-Kettering Cancer Center. Dr. McKiernan's clinical practice is focused on urologic oncology and particularly on surgical therapy in high-risk patients with bladder and kidney cancers. Dr. McKiernan evaluates and treats over 1,000 patients with bladder cancer every year. His research, funded by NIH and biotechnology industry grants, focuses on developing novel therapeutics for bladder cancer treatment as well as comparative effectiveness research in urologic oncology. In the management of kidney and bladder cancer, he has special expertise in organ preservation and reconstructive surgery to maximize quality of life. Dr. McKiernan's research has been published in Cancer, Cancer Research, the Journal of Clinical Oncology, JAMA Oncology, Journal of Urology, Urologic Oncology, and Urology. He has authored and co-authored more than 220 scientific articles and book chapters on urologic cancer and related issues.For the past 10 years, he has directed a research team at Columbia University Medical Center investigating quality outcomes and effectiveness in urologic cancer surgery. He has served as the Vice Chairman for the AJCC TNM Staging Task Force, Co-Chair of the AUA Guidelines Panel on non-muscle invasive bladder cancer, as well as on the American Board of Urology and Society of Urologic Oncology Examination Committees. In addition, Dr. McKiernan is the principal investigator of the NIH-funded clinical trials program of experimental therapeutics in bladder cancer at Columbia University/NYPH, which is investigating new agents for bladder preservation in patients whose cancer has recurred after standard therapy. In collaboration with researchers at Columbia's Herbert Irving Comprehensive Cancer Center, his team continues to develop new therapeutic strategies for managing bladder cancer. Dr. Mckiernan is rated as a Distinguished provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Bladder Cancer, Muscle Invasive Bladder Cancer, Urothelial Cancer, Cystectomy, and Nephrectomy.

Alexander I. Sankin, MD, is Professor, Urology at Montefiore Einstein. His clinical specialty is surgical approaches to treating urological malignancies, including prostate, testicular, renal and bladder cancer. Dr. Sankin is rated as an Experienced provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Non-Muscle Invasive Bladder Cancer, Nephrectomy, and Ureteroscopy.

Ahmed Aboumohamed, MD is an Attending Physician and a Professor in the Department of Urology at Montefiore and our Albert Einstein College of Medicine. Dr. Aboumohamed's areas of expertise include urology, urologic oncology, minimally invasive and robotic surgery, and urologic reconstruction. Dr. Aboumohamed is rated as an Experienced provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Bilateral Hydronephrosis, Bladder Cancer, Hydronephrosis, Cystectomy, and Nephrectomy.

Dr. Kara L. Watts, Associate Professor of Urology, joined the urology faculty at Montefiore in 2016. She completed a fellowship in Quality and Performance Improvement in Healthcare and an extended observership in focal ablation for prostate cancer in the UK. She serves as the Director of Quality Assurance and Improvement for the Department of Urology and leads the prostate cancer screening program. Dr. Watts is rated as an Experienced provider by MediFind in the treatment of Clear Cell Sarcoma. Her top areas of expertise are Prostate Cancer, Kidney Stones, Muscle Invasive Bladder Cancer, Vasectomy, and Ureteroscopy.

David Loeb, MD, PhD, is Chief, Pediatric Hematology, Oncology and Cellular Therapy at Children’s Hospital at Montefiore and Professor, Pediatrics and Professor, Developmental and Molecular Biology at Montefiore Einstein. His clinical work focuses on tumors of connective tissue, such as bone and muscle. He also has expertise in the care of children with other solid tumors. As a member of the bone marrow transplantation team, Dr. Loeb also cares for patients with acute leukemias and has expertise in the application of immunotherapy to childhood cancer. Dr. Loeb is rated as an Experienced provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Ewing Sarcoma, Osteosarcoma, Adult Soft Tissue Sarcoma, and Bone Tumor.

Caroline Hwang is a Hematologist in Bronx, New York. Dr. Hwang is rated as a Distinguished provider by MediFind in the treatment of Clear Cell Sarcoma. Her top areas of expertise are Chromophobe Renal Cell Carcinoma, Clear Cell Sarcoma, WT1-Related Wilms Tumor Syndromes, and Colorectal Cancer.

Marc Janis is a Urologist in Mount Vernon, New York. Dr. Janis is rated as an Experienced provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Male Pseudohermaphroditism with Gynecomastia, Eunuchoidism Familial Hypogonadotropic, Testicular Failure, Ureteroscopy, and Prostatic Artery Embolization.

James Wysock is a Urologist in New York, New York. Dr. Wysock is rated as an Advanced provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Prostate Cancer, Urachal Cyst, Renal Cell Carcinoma (RCC), Nephrectomy, and Prostatectomy.

Michael Stifelman is a Urologist in Hackensack, New Jersey. Dr. Stifelman is rated as a Distinguished provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Renal Cell Carcinoma (RCC), UPJ Obstruction, Retroperitoneal Fibrosis, Nephrectomy, and Ureteral Reconstruction.

Robert Alter is an Otolaryngologist in Hackensack, New Jersey. Dr. Alter is rated as a Distinguished provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Urothelial Cancer, Endoscopy, and Nephrectomy.

Eric Goldman is a primary care provider, practicing in Internal Medicine in Bronx, New York. Dr. Goldman is rated as an Experienced provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Familial Colorectal Cancer, Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer, and Ascariasis. Dr. Goldman is currently accepting new patients.

Michael Gross is a Urologist in Bronx, New York. Dr. Gross has been practicing medicine for over 44 years and is rated as an Experienced provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Balanitis, Enlarged Prostate (BPH), Urinary Tract Infection in Children, Urinary Tract Infection (UTI), and Prostatectomy.

Tarek Elrafei is an Oncologist in Bronx, New York. Dr. Elrafei is rated as an Experienced provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Cervical Cancer, Neuroendocrine Carcinoma of the Cervix, Breast Cancer, Bone Marrow Aspiration, and Thrombectomy.

Guarionex Decastro is a Urologist in New York, New York. Dr. Decastro is rated as an Advanced provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Nephrectomy. Dr. Decastro is currently accepting new patients.

Dr. Stein is an Associate Professor of Medical Oncology at Columbia University Medical Center. He is a recognized expert in field of genitourinary oncology – treating patients with prostate, kidney, bladder and testicular cancers. He is also a member of the Experimental Therapeutics program, investigating novel therapies across all solid tumors. In addition to providing standard therapies for the treatment of genitourinary cancers such as hormonal therapy, molecularly targeted therapy and chemotherapy, Dr. Stein leads multiple investigator initiated and industry sponsored clinical trials. Dr. Stein has a particular interest in the development of novel immune therapies for the treatment of prostate cancer, both in men with early recurrence of prostate cancer as well as in men with more advanced prostate cancer. He is also helping to lead two national trials in kidney cancer sponsored by the National Cancer Institute.Dr. Stein received his B.S. in Molecular Biophysics and Biochemistry from Yale University. He earned his medical degree at New York Medical College, receiving the graduation award in oncology for his published research. He completed a residency in internal medicine at Montefiore Medical Center, and a fellowship in Hematology and Medical Oncology at Mount Sinai Medical Center. Prior to joining Columbia University, Dr. Stein practiced genitourinary oncology for 13 years at Rutgers University and has been an author on over 60 publications including guidelines for assessing the efficacy of new drugs in prostate cancer and recommendations for the use of immunotherapy to treat prostate cancer. Dr. Stein is rated as an Advanced provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, Renal Cell Carcinoma (RCC), and Prostate Cancer.

"Christopher B. Anderson, MD, Associate Professor of Urology at CUMC, joined the Department of Urology in September 2015. He specializes in cancers of the bladder, prostate, kidney, testis and penis and performs both open and robotic surgeries. Dr. Anderson completed his medical degree from Northwestern University, completed his urology residency at Vanderbilt University, and then spent two years at Memorial Sloan Kettering Cancer Center as a fellow in urologic oncology. Following his residency, Dr. Anderson completed a urologic oncology fellowship at Memorial Sloan Kettering Cancer Center and obtained a Master of Public Health degree from Harvard University.Dr. Anderson's research interests include factors that influence the quality of surgery, access to care for patients with bladder cancer, outcomes after robotic prostatectomy, and active surveillance strategies for men with prostate cancer. Dr. Anderson has published several peer-reviewed articles and was recognized as ""Best Reviewer"" in 2014 by The Journal of Urology and in 2016 by Cancer.Dr. Anderson has clinical expertise in robotic prostatectomy for the treatment of prostate cancer, radical cystectomy with orthotopic neobladder for patients with bladder cancer, and partial nephrectomy for the treatment of kidney tumors. He also specializes in the multidisciplinary management of men with testicular cancer, including the use of primary and post-chemotherapy retroperitoneal lymph node dissection. He is currently the site leader for several clinical trials investigating the use of immunotherapy in patients with invasive and non-invasive bladder cancer.". Dr. Anderson is rated as an Advanced provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Bladder Cancer, Muscle Invasive Bladder Cancer, Urothelial Cancer, Cystectomy, and Nephrectomy.

Lee Richstone, MD is the Chairman of Urology and Director of Urology Services for the Western Region. He is also Director of Laparoscopic and Robotic Surgery at Lenox Hill Hospital and System Vice Chairman for Education for Northwell Health Urology. Dr. Richstone is Professor of Urology at The Hofstra-Northwell School of Medicine. Dr. Richstone completed medical school at the Cornell University Medical College in New York City. There he won early acceptance into Alpha Omega Alpha (AOA), the prestigious national medical honor society. He pursued his urologic training and chief residency at New York Presbyterian (Weill-Cornell) and Memorial Sloan Kettering hospitals. Dr. Richstone completed his fellowship training in urologic laparoscopic and robotic surgery and joined the North Shore Long Island Jewish Health System in 2007 as Director of Laparoscopic and Robotic Surgery. He then served as Chief of Urology for the North Shore University Hospital, then Chief of Urology at the Long Island Jewish Medical Center, before assuming the role of Chairman of Urology at Lenox Hill Hospital in Manhattan. Dr. Richstone is an internationally recognized urologic surgeon who has helped pioneer laparoscopic and robotic surgery for cancer of the prostate, kidney and bladder, as well as for various forms of urinary obstructions. He has over 90 peer-reviewed publications in leading national and international journals including The Journal of Urology, Urology, The British Journal of Urology, The Journal of Endourology, Cancer, and Cell.Dr. Richstone is a robotic surgery specialist having performed well over 1000 operations. This includes surgeries for prostate, kidney and bladder cancer and complex neobladder reconstructions completely robotically. His focus is on preserving urinary continence and sexual function. Dr. Richstone has also pioneered Laparoendoscopic Single Site Surgery (LESS), where entire laparoscopic operations are performed only through the belly button. Dr. Richstone is one of only a few surgeons in the United States to have performed single site partial nephrectomy and prostatectomy.Dr. Richstone is a member of the Society of Urologic Oncology (SUO), the America Urological Association (AUA), and the Endourological Society (EUS). Dr. Richstone is the recipient of numerous honors and awards, including acceptance into Alpha Omega Alpha (AOA), the E. Darracott Vaughan Prize for Excellence in Urology (2000), The Ferdinand C. Valentine Urology Essay Prize (First Place, 2005), The American Urological Association-Ambrose Reed Socioeconomic Essay Contest (First Place, 2005), and the Weill-Cornell Distinguished House Officer Award (2005). Dr. Richstone was awarded the Stryker and Nagamatsu Fellowship (2007), and won first prize at the Endourology Society Fellowship Paper Award the same year. Dr. Richstone won first prize at the AUA Research Foundation for Outstanding Research awarded at the 2010 AUA National Meeting in San Francisco. Dr. Richstone is rated as an Advanced provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Bladder Cancer, Renal Cell Carcinoma (RCC), Muscle Invasive Bladder Cancer, Cystectomy, and Nephrectomy.